Cartesian Therapeutics Inc
RNAC
Market Cap$153.65M
Close$
$-8.19
131% downside
Current Fair Value
131% downsideOvervalued by 131% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $153.65 Million |
|---|---|
| Enterprise Value | $60.69 Million |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-0.23 |
| Beta | 0.0 |
| Outstanding Shares | 155,204,182 |
| Avg 30 Day Volume | 1,173,765 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -4.25 |
|---|---|
| PEG | -2.62 |
| Price to Sales | - |
| Price to Book Ratio | -26.43 |
| Enterprise Value to Revenue | 2.34 |
| Enterprise Value to EBIT | -0.75 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.17 |
| Debt to Equity | -0.09 |
Revenue Sources
No data
ESG Score
No data
About Cartesian Therapeutics Inc
81 employees
CEO: Carsten Brunn selecta biosciences, inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses. selecta plans to combine its tolerogenic synthetic vac...